Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials
16 mai 2019 00h59 HE
|
Symphogen A/S
Sym021 a novel anti-PD1 compound currently in Phase 1 clinical trials Copenhagen, 16 May 2019 – Symphogen, a private clinical stage oncology focused biopharmaceutical company with a productive...
Antibody Drug Market Expected to Gain $30 Billion Through 2022
03 oct. 2017 14h30 HE
|
BCC Research
WELLESLEY, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- An increase in research and development, burgeoning industry competition and evolving technologies are steering the antibody drug market into a...